Methotrexate for psoriasis: Current European practice. A postal survey

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 2, 2005, Pages 196-202

  Boffa, M J ^a  

^a Sir Paul Boffa Hospital   (Malta)

Author keywords

European dermatologists; Methotrexate; Postal survey; Psoriasis

Indexed keywords

CYCLOSPORIN; ETRETIN; FOLIC ACID; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PSORALEN;

ARTICLE; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INFORMATION; DRUG MONITORING; DRUG UTILIZATION; EUROPE; HEMATOLOGIC DISEASE; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MEDICAL SOCIETY; MEDICAL SPECIALIST; NAUSEA; PHOTOTHERAPY; POSTAL MAIL; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; QUESTIONNAIRE;

BIOPSY; BLOOD CELL COUNT; DATA COLLECTION; DRUG ADMINISTRATION SCHEDULE; FOLIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; METHOTREXATE; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; QUESTIONNAIRES;

EID: 16244392816     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.01140.x     Document Type: Article

References (28)

1. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-156.
2. Roenigk HH, Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38 478-485.
3. Chalmers RJG, Boffa MJ. Current management of psoriasis: methotrexate. J Dermatol Treat 1997; 8: 41-44, 53-55.
4. Peckham P, Weinstein G, McCullough JL. The treatment of severe psoriasis. Arch Dermatol 1987; 123: 1303-1307.
5. Petrazzuoli M, Rothe MJ, Grin-Jorgensen C et al. Monitoring patients taking methotrexate for hepatotoxicity. Does the standard of care match published guidelines? J Am Acad Dermatol 1994; 31: 969-977.
6. Bisland DJ, Rhodes LE, Zaki I et al. PUVA and methotrexate therapy of psoriasis: how closely do dermatology departments follow treatment guidelines? Br J Dermatol 1994; 131: 220-225.
7. Weinstein GD, Frost P. Methotrexate for psoriasis - a new therapeutic schedule. Arch Dermatol 1971; 103: 33-38.
8. Zanolli MD, Sherertz EF, Hedberg AE. Methotrexate: anti-inflammatory or antiproliferative? J Am Acad Dermatol 1990; 22: 523-524.
9. Boffa MJ, Chalmers RJG. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399-408.
10. Leeb BF, Witzmann G, Ogris E et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995; 13: 459-463.
11. Hendel J, Nyfors A. Impact of methotrexate therapy on folate status of psoriatic patients. Clin Exp Dermatol 1985; 10: 30-35.
12. Weinblatt ME, Fraser P. Elevated mean corpuscular volume in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1989; 32: 1592-1596.
13. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate treatment for psoriasis. J Am Acad Dermatol 1993; 28: 466-469.
14. Ortiz Z, Shea B, Suarez-Almazor ME et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials. J Rheumatol 1998; 25: 36-43.
15. Van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44 1515-1524.
16. Morgan SI, Alarcon GS, Krumdieck CL. Folic acid supplementation during methotrexate therapy: it makes sense. J Rheumatol 1993; 20: 929-930.
17. Kirby B, Lyon CC, Griffiths CEM, Chalmers RJG. The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. Clin Exp Dermatol 2000; 25: 265-268.
18. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 1997; 24: 2230-2232.
19. Weinstein G, Roenigk H, Maibach H, Cosmides J. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108: 36-42.
20. Boffa MJ, Chalmers RJG, Haboubi NY et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774-778.
21. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-210.
22. Lanse SB, Arnold GL, Gowans JDC, Kaplan MM. Low incidence of hepatotoxicity associated with long-term low-dose, oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis and rheumatoid arthritis: an acceptable risk/benefit ratio. Dig Dis Sci 1985; 30: 104-109.
23. Kaplan MM. Methotrexate hepatotoxicity and the premature reporting of Mark Twain's death: both grossly exaggerated. Hepatology 1990; 2: 784-786.
24. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy - A multicentre, retrospective study on 68 276 biopsies. J Hepatol 1986; 2: 165-173.
25. Boffa MJ, Smith A, Chalmers RJG et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135 538-544.
26. Zacharie H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 143: 100-103.
27. Chalmers RJG, Boffa MJ, Kirby B, Smith A. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 2001; 44: 879-880.
28. Mitchell DM, Johnson RJ, Testa HJ et al. Ultrasound and radionuclide scans - poor indicators of liver damage in psoriatic patients treated with methotrexate. Clin Exp Dermatol 1987; 12 243-245.